Adaptimmune Therapeutics

Adaptimmune's mission is to develop novel, engineered TCR T-cell therapies capable of targeting a broad range of solid tumors by recognizing intracellular cancer proteins. Its key achievement was advancing multiple assets into late-stage trials before executing a strategic transformation in 2025, selling its lead clinical programs (including afami-cel and lete-cel) to US WorldMeds, delisting from Nasdaq, and restructuring its leadership. The company's current strategy is to maximize value from its remaining earlier-stage pipeline targeting PRAME and CD70, while significantly reducing operational and public company costs as a streamlined, OTC-quoted entity.

Proprietary T-cell receptor (TCR) T-cell platform focused on engineering high-affinity TCRs to target intracellular cancer proteins presented on the cell surface via HLA, enabling targeting of a broad range of solid tumors.

Adaptimmune now competes as an early-stage platform company against well-funded TCR players like Immunocore, Immatics, and large pharma partners (GSK, BMS). Its competitive edge lies in its historical expertise and IP, but it lacks the capital and late-stage assets of its peers.